Replies to post #12403 on GTC Biotherapeutics (fka GTCB)

[jessellivermore]

perhaps GTCB has not extracted full value in its own partnership dealings to date.

Yes this Bayer deal makes it sound like LFB stuck it to them.
Hopefully they will do better in the future when their balance sheet improves.....survival is a bia**h....

[DewDiligence]

MAXY is holding a CC at 11:30 am ET to discuss the Bayer deal. Access to the webcast is at: http://www.maxygen.com/ .

[alertmeipp]

>$90 millions upfront - Dew, will GTCB's potential FoB deals be anywhere close to that?

90 millions - that's HUGE.

[DewDiligence]

Addendum on Bayer-MAXY FVIIa deal:

1. Although Maxy-VII was the impetus for the deal, Bayer also acquired MAXY’s FVIII and FIX analogs, which are much earlier in development than Maxy-VII (i.e. not ready for human testing) and had not been previously disclosed.

2. With this deal, MAXY is completely out of the hematology arena and is focused entirely on autoimmune diseases.

3. The $30M milestone will be earned by MAXY when Maxy-VII enters phase-2 trials and patent coverage for the compound issues in the US and EU.

[DewDiligence]

MAXY does it again, striking a lucrative deal for MAXY-4:
#msg-32278299.

Why can’t GTC ink deals like this? MAXY’s two recent deals (today’s and the one in July for the FVIIa program) make GTC’s partnership with LFB look like some of kind of sick joke.